FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310106462> ?p ?o ?g. }

• W4310106462 endingPage "970" @default.
• W4310106462 startingPage "969" @default.
• W4310106462 abstract "The current first-line treatment for Hemophilia A patients is factor replacement therapy and/or bi-specific antibodies; however, these treatments require continuous infusions over the course of the patient's life, and patients continue to have breakthrough bleeds, representing a high unmet need for a non-viral gene therapy. Unlike conventional AAV gene therapies, our proprietary piggyBac® DNA delivery platform facilitates stable genomic insertion of a therapeutic transgene as a means of developing lifelong cures of hereditary genetic deficiencies such as hemophilia A. The Super piggyBac (SPB) transposase enzyme functions by excising a DNA cargo flanked by SPB recognition ITRs and inserting into TTAA genomic sites. We have developed a non-viral, nanoparticle-based delivery system to enable piggyBac-based gene therapy. This system entails two liver-tropic nanoparticles: a lipid nanoparticle encapsulating the SPB transposase formulated as mRNA, and a second nanoparticle encapsulating a plasmid comprising the human FVIII gene, promoter, and piggyBac ITRs. This non-viral strategy provides certain advantages over AAV-based approaches: increased transgene cargo capacity beyond 4.7 kb, stable integration of the FVIII transgene into the genome, the potential for re-dosing, and potentially simpler manufacturing processes, relative to AAV-based vector production. Optimization of the human FVIII transposon was conducted, specifically to elucidate the role of promoter, transgene sequence, and UTR elements in FVIII antigen levels. A panel of transposons was prepared and FVIII levels assessed following single administration in vivo to wild type mice. The transposons with the highest FVIII performance were subsequently evaluated in long-term efficacy studies. Initial proof-of-concept studies demonstrated that LNPs separately optimized for SPB mRNA or FVIII transposon DNA delivery can be co-administered intravenously to mice. We observed that transposase mRNA delivered to the liver is converted to protein rapidly and expressed for several days. Transposon DNA delivered to mouse liver results in expression of functional human FVIII protein, though at sub-therapeutic levels at the doses evaluated here. Co-administration of the transposon and transposase nanoparticles resulted in sustained FVIII antigen levels in the anticipated therapeutic range (>50% of normal) in wild type animals. We observed a more dramatic response when the dual-nanoparticle system was evaluated in neonatal (post-natal day 1) wild type mice. Mice were co-administered the SPB mRNA LNP and the human FVIII transposon nanoparticle. Control mice were co-administered the same dose of a catalytically dead SPB transposase, which is unable to mediate genomic integration. FVIII protein reached therapeutic levels in plasma and were sustained over the full study duration (5 months), whereas control animals exhibited negligible (<2%) human FVIII levels. These findings illustrate the utility of the piggyBac DNA delivery system for treating genetic disease early in life, enabled by stable integration. Thus, piggyBac platform avoids the transient efficacy typical of conventional non-integrating gene therapy approaches. To further validate this long-term durability, a six-month efficacy study was conducted in a mouse model of hemophilia A (FVIII exon 16−/−/CD4−/−, C57BL/6). This model is deficient in FVIII as well as CD4, allowing measurement of FVIII activity levels afforded the absence of an immune response to human FVIII. We observed that a single treatment yielded 30 - 150% of human FVIII activity in a dose-responsive manner, which was generally sustained over the duration of the study. Mice treated with the same dose of human FVIII transposon and the catalytically dead transposase exhibited negligible (<2%) human FVIII activity at all timepoints evaluated. In conclusion, our results demonstrate the novelty of our piggyBac® platform and approach in providing a potential lifelong functional cure for hemophilia A. By providing stable transgene expression through genomic integration, this technology has the potential to greatly improve the lives of hemophilia A patients." @default.
• W4310106462 created "2022-11-30" @default.
• W4310106462 creator A5001295981 @default.
• W4310106462 creator A5007360666 @default.
• W4310106462 creator A5022654535 @default.
• W4310106462 creator A5025709735 @default.
• W4310106462 creator A5027324518 @default.
• W4310106462 creator A5042978093 @default.
• W4310106462 creator A5051217872 @default.
• W4310106462 creator A5054461692 @default.
• W4310106462 creator A5061034661 @default.
• W4310106462 creator A5066805174 @default.
• W4310106462 creator A5069141166 @default.
• W4310106462 creator A5070672238 @default.
• W4310106462 creator A5074367169 @default.
• W4310106462 creator A5083116189 @default.
• W4310106462 creator A5085163852 @default.
• W4310106462 date "2022-11-15" @default.
• W4310106462 modified "2023-10-16" @default.
• W4310106462 title "Sustained Factor VIII Activity Following Single Dose of Non-Viral Integrating Gene Therapy" @default.
• W4310106462 doi "https://doi.org/10.1182/blood-2022-167919" @default.
• W4310106462 hasPublicationYear "2022" @default.
• W4310106462 type Work @default.
• W4310106462 citedByCount "0" @default.
• W4310106462 crossrefType "journal-article" @default.
• W4310106462 hasAuthorship W4310106462A5001295981 @default.
• W4310106462 hasAuthorship W4310106462A5007360666 @default.
• W4310106462 hasAuthorship W4310106462A5022654535 @default.
• W4310106462 hasAuthorship W4310106462A5025709735 @default.
• W4310106462 hasAuthorship W4310106462A5027324518 @default.
• W4310106462 hasAuthorship W4310106462A5042978093 @default.
• W4310106462 hasAuthorship W4310106462A5051217872 @default.
• W4310106462 hasAuthorship W4310106462A5054461692 @default.
• W4310106462 hasAuthorship W4310106462A5061034661 @default.
• W4310106462 hasAuthorship W4310106462A5066805174 @default.
• W4310106462 hasAuthorship W4310106462A5069141166 @default.
• W4310106462 hasAuthorship W4310106462A5070672238 @default.
• W4310106462 hasAuthorship W4310106462A5074367169 @default.
• W4310106462 hasAuthorship W4310106462A5083116189 @default.
• W4310106462 hasAuthorship W4310106462A5085163852 @default.
• W4310106462 hasConcept C102230213 @default.
• W4310106462 hasConcept C104317684 @default.
• W4310106462 hasConcept C111599444 @default.
• W4310106462 hasConcept C135983454 @default.
• W4310106462 hasConcept C141231307 @default.
• W4310106462 hasConcept C14430832 @default.
• W4310106462 hasConcept C153911025 @default.
• W4310106462 hasConcept C159047783 @default.
• W4310106462 hasConcept C172510086 @default.
• W4310106462 hasConcept C32470452 @default.
• W4310106462 hasConcept C40767141 @default.
• W4310106462 hasConcept C43953973 @default.
• W4310106462 hasConcept C4918238 @default.
• W4310106462 hasConcept C54355233 @default.
• W4310106462 hasConcept C86803240 @default.
• W4310106462 hasConceptScore W4310106462C102230213 @default.
• W4310106462 hasConceptScore W4310106462C104317684 @default.
• W4310106462 hasConceptScore W4310106462C111599444 @default.
• W4310106462 hasConceptScore W4310106462C135983454 @default.
• W4310106462 hasConceptScore W4310106462C141231307 @default.
• W4310106462 hasConceptScore W4310106462C14430832 @default.
• W4310106462 hasConceptScore W4310106462C153911025 @default.
• W4310106462 hasConceptScore W4310106462C159047783 @default.
• W4310106462 hasConceptScore W4310106462C172510086 @default.
• W4310106462 hasConceptScore W4310106462C32470452 @default.
• W4310106462 hasConceptScore W4310106462C40767141 @default.
• W4310106462 hasConceptScore W4310106462C43953973 @default.
• W4310106462 hasConceptScore W4310106462C4918238 @default.
• W4310106462 hasConceptScore W4310106462C54355233 @default.
• W4310106462 hasConceptScore W4310106462C86803240 @default.
• W4310106462 hasIssue "Supplement 1" @default.
• W4310106462 hasLocation W43101064621 @default.
• W4310106462 hasOpenAccess W4310106462 @default.
• W4310106462 hasPrimaryLocation W43101064621 @default.
• W4310106462 hasRelatedWork W1587611090 @default.
• W4310106462 hasRelatedWork W2017523998 @default.
• W4310106462 hasRelatedWork W204748332 @default.
• W4310106462 hasRelatedWork W2146923102 @default.
• W4310106462 hasRelatedWork W2397865238 @default.
• W4310106462 hasRelatedWork W2606105109 @default.
• W4310106462 hasRelatedWork W3037704716 @default.
• W4310106462 hasRelatedWork W4250867061 @default.
• W4310106462 hasRelatedWork W43273318 @default.
• W4310106462 hasRelatedWork W657852157 @default.
• W4310106462 hasVolume "140" @default.
• W4310106462 isParatext "false" @default.
• W4310106462 isRetracted "false" @default.
• W4310106462 workType "article" @default.